ClinicalTrials.gg

Program

Filgrastim

Also written as “filgrastim”, “Neupogen (filgrastim)” and “Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous”.

Its studies are mostly in Neutropenia · Breast Neoplasms · ST Elevation Myocardial Infarction · Multiple Myeloma · Lymphoma, Non-Hodgkin, led by 15 companies.

Furthest: phase 4, since Nov 2, 199927 company-led studies, 1 open or runningNext primary completion: Apr 7, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Amgen50 open or runningphase 2since Nov 2, 1999Nov 2, 1999none ahead
Pfizer50 open or runningphase 2since Nov 5, 2013Nov 5, 2013none ahead
Biocad30 open or runningphase 3since Apr 2, 2014Mar 30, 2012none ahead
Dong-A ST20 open or runningphase 3since Nov 10, 2017Mar 22, 2016none ahead
Novartis20 open or runningphase 4since May 8, 2013Jan 13, 2012none ahead
axaron-bioscience-ag10 open or runningphase 2since Aug 18, 2005Aug 18, 2005none ahead
Azidus Brasil10 open or runningphase 1since Mar 6, 2012Mar 6, 2012none ahead
BioGeneric Pharma11 open or runningphase 1since Oct 4, 2026Oct 4, 2026Apr 7, 2027phase 1 · NCT07877467
Clinique Ovo10 open or runningphase 3since Mar 19, 2014Mar 19, 2014none ahead
CSL10 open or runningphase 1since May 31, 2019May 31, 2019none ahead
Dong-A Pharmaceutical10 open or runningphase 1since Mar 15, 2013Mar 15, 2013none ahead
Eurofarma Laboratorios10 open or runningphase 3since Mar 2, 2010Mar 2, 2010none ahead
hangzhou-jiuyuan-gene-engineering-co-ltd10 open or runningphase 2since Aug 6, 2013Aug 6, 2013none ahead
proteonomix-inc10 open or runningphase 1since Oct 11, 2012Oct 11, 2012none ahead
sygnis-bioscience-gmbh-co-kg10 open or runningphase 2since Jun 24, 2009Jun 24, 2009none ahead

Also a collaborator on its studies: celerion, sandoz-gmbh and numoda.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 12 studies since Nov 2, 1999.

  1. Mar 15, 2013Dong-A Pharmaceutical's first study: phase 1 study in Diabetic NeuropathiesNew to Dong-A PharmaceuticalDong-A Pharmaceutical · NCT01820715 · 31 enrolled · Korea, Republic of
  2. May 8, 2013Phase 4 study in Neutropenia, severe chronicNovartis · NCT01859637 · 6 enrolled · Germany, Sweden
  3. Aug 6, 2013hangzhou-jiuyuan-gene-engineering-co-ltd's first study: phase 2 study in NeutropeniaNew to hangzhou-jiuyuan-gene-engineering-co-ltdhangzhou-jiuyuan-gene-engineering-co-ltd · NCT01918241 · 200 enrolled · China
  4. Nov 5, 2013Pfizer's first study: phase 2 study in Advanced Multiple MyelomaNew to PfizerPfizer · NCT01989325 · 77 enrolled · United States
  5. Mar 19, 2014Clinique Ovo's first study: phase 3 study in InfertilityNew to Clinique OvoClinique Ovo · NCT02149277 · 15 enrolled · Canada
  6. Mar 19, 2014Phase 2 study in Advanced Multiple MyelomaPfizer · NCT02092922 · 154 enrolled · United States, Belgium, Canada and more
  7. Apr 2, 2014Phase 3 study in NeutropeniaBiocad · NCT02104830 · 135 enrolled · Russian Federation
  8. Mar 22, 2016Dong-A ST's first study: phase 1 study in HealthyNew to Dong-A STDong-A ST · NCT02725086 · 56 enrolled · Korea, Republic of
  9. Apr 1, 2016Phase 1 study in LeukocytosisBiocad · NCT02762799 · 60 enrolled
  10. May 6, 20162 phase 1 studies in NeutropeniaPfizer · NCT02766647, NCT02766634
  11. Sep 30, 2016Phase 1 study in Healthy VolunteersPfizer · NCT02923791 · 256 enrolled · United States
  12. Nov 10, 2017Phase 3 study in Breast NeoplasmsDong-A ST · NCT03343145 · 143 enrolled · Indonesia
  13. May 31, 2019CSL's first study: phase 1 study in Hidradenitis SuppurativaNew to CSLCSL · NCT03972280 · 39 enrolled · Australia, Denmark, Germany
  14. Oct 4, 2026BioGeneric Pharma's first study: phase 1 study in NeutropeniaNew to BioGeneric PharmaBioGeneric Pharma · NCT07877467 · 50 planned

Ahead

  1. Apr 7, 2027Primary completion: phase 1 study in NeutropeniaBioGeneric Pharma · NCT07877467

TargetBeta

CSF3R →read by rule
“Granulocyte colony stimulating factor receptor agonist”ChEMBL 37, by rule

Other programs on CSF3R

ProgramCompanyFurthest phaseStudies
pegfilgrastimruleAmgenphase 452
anumigilimabruleCSLphase 24

Studies

All 27 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07877467Neutropenia1Not yet recruitingBioGeneric PharmaApr 7, 202750
NCT03972280Hidradenitis Suppurativa · Australia, Denmark, Germany1CompletedCSLOct 4, 202239
NCT03343145Breast Neoplasms · Indonesia3CompletedDong-A STJan 28, 2019143
NCT02923791Healthy Volunteers · United States1CompletedPfizerJan 2017256
NCT02766647Neutropenia · United States1CompletedPfizerFeb 201624
NCT02766634Neutropenia · United States1CompletedPfizerJun 201660
NCT02762799Leukocytosis1CompletedBiocadNov 11, 201660
NCT02725086Healthy · Korea, Republic of1CompletedDong-A STApr 201656
NCT02104830Neutropenia · Russian Federation3CompletedBiocadJun 2014135
NCT02149277Infertility · Canada3TerminatedClinique OvoDec 201715
NCT02092922Advanced Multiple Myeloma · United States, Belgium, Canada and more2CompletedPfizerJul 2016154
NCT01989325Advanced Multiple Myeloma · United States2CompletedPfizerFeb 201677
NCT01918241Neutropenia · China2UNKNOWNhangzhou-jiuyuan-gene-engineering-co-ltdJan 2016200
NCT01859637Neutropenia, severe chronic · Germany, Sweden4TerminatedNovartisMar 20146
NCT01820715Diabetic Neuropathies · Korea, Republic of1CompletedDong-A PharmaceuticalApr 201331
NCT01711073End Stage Liver Disease · United States1UNKNOWNproteonomix-incSep 201315
NCT01569087Neutropenia · Russian Federation2CompletedBiocadJan 201360
NCT01549301Healthy Subjects · Brazil1CompletedAzidus BrasilAug 2013128
NCT01519700Breast Neoplasms · Czech Republic, Hungary, Latvia and more3CompletedNovartisJun 2013218
NCT01079676Neutropenia in Breast Cancer · Brazil3CompletedEurofarma LaboratoriosApr 2011220
NCT00927836Ischemic Stroke · Austria, Belgium, Czech Republic and more2Completedsygnis-bioscience-gmbh-co-kgNov 2011328
NCT00132470Stroke · Germany2Completedaxaron-bioscience-ag42
NCT00117897Lymphoma, Non-Hodgkin2CompletedAmgen
NCT00117455Lymphoma, Non-Hodgkin2CompletedAmgen
NCT00006215Lung Neoplasms · United States2UNKNOWNAmgen
NCT00005958Urinary Bladder Neoplasms · United States2UNKNOWNAmgen
NCT00002126HIV Infections · United States, Canada2CompletedAmgen250

How it is read

Names in the registry

  • “Filgrastim”, 11 entries
  • “filgrastim”, 4 entries
  • “Neupogen (filgrastim)”, 2 entries
  • “Filgrastim, granulocyte-colony stimulating factor (G-CSF); subcutaneous”, 2 entries
  • “Leucostim®”, 2 entries

Codes read as this program: DA3030.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.